Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines

Greenlee, 2001, Cancer statistics, 2001, CA Cancer J Clin, 51, 15, 10.3322/canjclin.51.1.15 Hjalgrim, 2008, Infectious aetiologyof Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence, J Intern Med, 264, 537, 10.1111/j.1365-2796.2008.02031.x Ablashi, 2002, Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases, Clin Microbiol Rev, 15, 439, 10.1128/CMR.15.3.439-464.2002 Carbone, 2009, HIV-associated lymphomas and gamma-herpesviruses, Blood, 113, 1213, 10.1182/blood-2008-09-180315 Carbone, 2007, HHV-8-associated lymphoma: state-of-the-art review, Acta Haematol, 117, 129, 10.1159/000097459 Ganem, 1997, KSHV and Kaposi's sarcoma: the end of the beginning?, Cell, 91, 157, 10.1016/S0092-8674(00)80398-0 Ganem, 2006, KSHV infection and the pathogenesis of Kaposi's sarcoma, Annu Rev Pathol, 1, 273, 10.1146/annurev.pathol.1.110304.100133 Klass, 2005, Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma, Curr Opin Oncol, 17, 447, 10.1097/01.cco.0000172823.01190.6c Curreli, 2005, Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes, J Clin Invest, 115, 642, 10.1172/JCI200523334 An, 2004, Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas, Leukemia, 18, 1699, 10.1038/sj.leu.2403460 Toomey, 2001, Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma, Oncogene, 20, 7029, 10.1038/sj.onc.1204895 Sarek, 2007, Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas, J Clin Invest, 117, 1019, 10.1172/JCI30945 Hocqueloux, 2001, Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy, Aids, 15, 280, 10.1097/00002030-200101260-00023 Luppi, 2005, Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir, Leukemia, 19, 473, 10.1038/sj.leu.2403646 Halfdanarson, 2006, A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy, Ann Oncol, 17, 1849, 10.1093/annonc/mdl139 Bhatt, 2010, Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas, Blood, 115, 4455, 10.1182/blood-2009-10-251082 Bernard, 2008, Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise, Curr Pharm Des, 14, 2051, 10.2174/138161208785294654 Bakhle, 2001, COX-2 and cancer: a new approach to an old problem, Br J Pharmacol, 134, 1137, 10.1038/sj.bjp.0704365 Hull, 2005, Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?, Eur J Cancer, 41, 1854, 10.1016/j.ejca.2005.04.013 Hull, 2004, Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?, Molecular cancer therapeutics, 3, 1031, 10.1158/1535-7163.1031.3.8 Jones, 2002, von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis, Faseb J, 16, 264, 10.1096/fj.01-0589fje Jones, 1999, Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing, Nat Med, 5, 1418, 10.1038/70995 Kaur Saini, 2009, Chemopreventive response of diclofenac, a nonsteroidal anti-inflammatory drug in experimental carcinogenesis, Nutr Hosp, 24, 717 Chen, 2009, Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis, Apmis, 117, 176, 10.1111/j.1600-0463.2008.00004.x Kobayashi, 2005, Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells, Eur J Haematol, 75, 212, 10.1111/j.1600-0609.2005.00498.x He, 2006, Inhibition of human telomerase reverse transcriptase by nonsteroidal anti-inflammatory drugs in colon carcinoma, Cancer, 106, 1243, 10.1002/cncr.21694 He, 2008, Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP, Oncogene, 27, 2656, 10.1038/sj.onc.1210894 Liu, 2011, High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection, Clin Chim Acta, 412, 1081, 10.1016/j.cca.2011.02.028 Li, 2003, Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line, World J Gastroenterol, 9, 915, 10.3748/wjg.v9.i5.915 Ladetto, 2005, Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome, Blood, 105, 4784, 10.1182/blood-2004-11-4201 Zha, 2004, Cyclooxygenases in cancer: progress and perspective, Cancer Lett, 215, 1, 10.1016/j.canlet.2004.06.014 Wang, 2006, Prostaglandins and cancer, Gut, 55, 115, 10.1136/gut.2004.047100 Castellone, 2005, Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis, Science, 310, 1504, 10.1126/science.1116221 Fulton, 2006, Targeting prostaglandin E EP receptors to inhibit metastasis, Cancer Res, 66, 9794, 10.1158/0008-5472.CAN-06-2067 Majima, 2003, Prostanoid receptor signaling relevant to tumor growth and angiogenesis, Trends Pharmacol Sci, 24, 524, 10.1016/j.tips.2003.08.005 Piazuelo, 2006, Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus, Prostaglandins Other Lipid Mediat, 81, 150, 10.1016/j.prostaglandins.2006.09.002 Sugimoto, 2007, Prostaglandin E receptors, J Biol Chem, 282, 11613, 10.1074/jbc.R600038200 Wang, 2006, Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer, Cancer Lett, 242, 20, 10.1016/j.canlet.2005.10.030 Sharma-Walia, 2010, Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion, PLoS Pathog, 6, e1000777, 10.1371/journal.ppat.1000777 Paul, 2011, Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma, PLoS One, 6, e24379, 10.1371/journal.pone.0024379 George Paul, 2010, Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen, Cancer research, 70, 3697, 10.1158/0008-5472.CAN-09-3934 Sharma-Walia, 2006, Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpes virus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression, J Virol, 80, 6534, 10.1128/JVI.00231-06 Sharma-Walia, 2010, Nfat and Creb regulate Kaposi's sarcoma associated herpes virus (KSHV) induced cyclooxygenase-2 (Cox-2), J Virol, 84, 12733, 10.1128/JVI.01065-10 Sharma-Walia, 2012, COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-vFLIP, Oncogenesis, 1, 1, 10.1038/oncsis.2012.5 Bock, 2007, Celecoxib toxicity is cell cycle phase specific, Cancer Res, 67, 3801, 10.1158/0008-5472.CAN-06-3780 Schonthal, 2007, Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy, Br J Cancer, 97, 1465, 10.1038/sj.bjc.6604049 Reynolds, 2006, Biological interactions between herpesviruses and cyclooxygenase enzymes, Rev Med Virol, 16, 393, 10.1002/rmv.519 Shelby, 2005, Gamma-herpesvirus neoplasia: a growing role for COX-2, Microsc Res Tech, 68, 120, 10.1002/jemt.20226 Takada, 1991, An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA, Virus Genes, 5, 147, 10.1007/BF00571929 Yamamoto, 2000, Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs, FEBS Lett, 484, 153, 10.1016/S0014-5793(00)02145-1 Keery, 1988, AH6809, a prostaglandin DP-receptor blocking drug on human platelets, Br J Pharmacol, 94, 745, 10.1111/j.1476-5381.1988.tb11584.x Wilson, 2006, GW627368X (N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl] acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist, Br J Pharmacol, 148, 326, 10.1038/sj.bjp.0706726 Foudi, 2008, Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype, Br J Pharmacol, 154, 1631, 10.1038/bjp.2008.214 Shi, 2008, Clinical use and pharmacological properties of selective COX-2 inhibitors, Eur J Clin Pharmacol, 64, 233, 10.1007/s00228-007-0400-7 Kardosh, 2005, Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo, Cancer Biol Ther, 4, 571, 10.4161/cbt.4.5.1699 Jones, 1995, Infection of human endothelial cells with Epstein-Barr virus, J Exp Med, 182, 1213, 10.1084/jem.182.5.1213 McGettigan, 2006, Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2, JAMA, 296, 1633, 10.1001/jama.296.13.jrv60011 Sarita Rajender, 2010, Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer–a review, J Recept Signal Transduct Res, 30, 206, 10.3109/10799893.2010.488649 Smith, 2006, Common fragile sites, extremely large genes, neural development and cancer, Cancer Lett, 232, 48, 10.1016/j.canlet.2005.06.049 Martin, 2011, Hit proteins, mitochondria and cancer, Biochim Biophys Acta, 1807, 626, 10.1016/j.bbabio.2011.02.001 Murphy, 2011, Tissue inhibitors of metalloproteinases, Genome Biol, 12, 233, 10.1186/gb-2011-12-11-233 Liao, 2008, Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver, Int J Biochem Cell Biol, 40, 843, 10.1016/j.biocel.2007.04.008 Sperka, 2012, DNA damage checkpoints in stem cells, ageing and cancer, Nat Rev Mol Cell Biol, 13, 579, 10.1038/nrm3420 Zhao, 2012, Promoter methylation of tumor-related genes in gastric carcinogenesis, Histol Histopathol, 27, 1271 Overmeyer, 2011, Death pathways triggered by activated Ras in cancer cells, Front Biosci, 16, 1693, 10.2741/3814 Semenza, 2012, Molecular mechanisms mediating metastasis of hypoxic breast cancer cells, Trends Mol Med, 18, 534, 10.1016/j.molmed.2012.08.001 Esteller, 2003, Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg, Clin Immunol, 109, 80, 10.1016/S1521-6616(03)00208-0 Dehennaut, 2009, Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response, Bull Cancer, 96, E66, 10.1684/bdc.2009.0959 Szymanska, 2003, TP53 and mutations in human cancer, Acta Biochim Pol, 50, 231, 10.18388/abp.2003_3731 Craig, 2002, MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis, Leukemia, 16, 444, 10.1038/sj.leu.2402416 Paredes, 2012, Epithelial E- and P-cadherins: role and clinical significance in cancer, Biochim Biophys Acta, 1826, 297 Ehlin-Henriksson, 2006, Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells, Immunology, 117, 379, 10.1111/j.1365-2567.2005.02311.x Yuan, 2006, Virus and cell RNAs expressed during Epstein-Barr virus replication, J Virol, 80, 2548, 10.1128/JVI.80.5.2548-2565.2006 Ruf, 1999, Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma, Mol Cell Biol, 19, 1651, 10.1128/MCB.19.3.1651 Ruf, 2001, EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma, Curr Top Microbiol Immunol, 258, 153, 10.1007/978-3-642-56515-1_10 Di Bartolo, 2008, KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor, Blood, 111, 4731, 10.1182/blood-2007-09-110544 Shin, 2006, Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1, J Virol, 80, 2257, 10.1128/JVI.80.5.2257-2266.2006 Fries, 1996, Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene, J Virol, 70, 8653, 10.1128/JVI.70.12.8653-8659.1996 Kenney, 2001, Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents, Int J Cancer, 91, 89, 10.1002/1097-0215(20010101)91:1<89::AID-IJC1015>3.0.CO;2-U Polack, 1996, c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1, Proc Natl Acad Sci U S A, 93, 10411, 10.1073/pnas.93.19.10411 Man, 2007, Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells, Oncogene, 26, 3069, 10.1038/sj.onc.1210106 Matsusaka, 2011, Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes, Cancer Res, 71, 7187, 10.1158/0008-5472.CAN-11-1349 Kang, 2002, Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma, Am J Pathol, 160, 787, 10.1016/S0002-9440(10)64901-2 Ryan, 2010, Epstein-Barr virus-specific methylation of human genes in gastric cancer cells, Infect Agent Cancer, 5, 27, 10.1186/1750-9378-5-27 Lee, 2007, Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma, Biomed Pharmacother, 61, 520, 10.1016/j.biopha.2007.08.007 Kim, 2005, Silencing and CpG island methylation of GSTP1 is rare in ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas, Anticancer Res, 25, 4013 Zhou, 2005, Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models, Cancer Chemother Pharmacol, 56, 569, 10.1007/s00280-005-1017-0 Hutajulu, 2011, Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population, Mol Cancer, 10, 48, 10.1186/1476-4598-10-48 Seng, 2007, The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation, Oncogene, 26, 934, 10.1038/sj.onc.1209839 Dai, 2012, Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts, Virol J, 9, 77, 10.1186/1743-422X-9-77 Shan, 2007, Activation of proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial cells, J Mol Cell Cardiol, 42, 517, 10.1016/j.yjmcc.2006.08.004 Chandran, 2010, Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells, J Virol, 84, 2188, 10.1128/JVI.01334-09 Wang, 2007, Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway, Mol Carcinog, 46, 912, 10.1002/mc.20320 Hatton, 2012, Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas, PLoS One, 7, e42610, 10.1371/journal.pone.0042610 Fotheringham, 2012, Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through alphav-integrin membrane translocation, J Virol, 86, 10308, 10.1128/JVI.00853-12 de Oliveira, 2010, NF-kappaB signaling modulation by EBV and KSHV, Trends Microbiol, 18, 248, 10.1016/j.tim.2010.04.001 Flanagan, 2008, BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2, Cell Death Differ, 15, 580, 10.1038/sj.cdd.4402292 Pietrek, 2010, Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation, J Virol, 84, 8231, 10.1128/JVI.01696-09 Lee, 2005, Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome, J Virol, 79, 12173, 10.1128/JVI.79.19.12173-12184.2005 Yokoi, 1990, Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor, Immunology, 70, 100 Todd, 1996, EBV induces proliferation of immature human thymocytes in an IL-2-mediated response, J Immunol, 156, 4217, 10.4049/jimmunol.156.11.4217 Burkhardt, 1992, An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases, J Virol, 66, 5161, 10.1128/JVI.66.8.5161-5167.1992 Chen, 2010, Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma–associated Herpesvirus Lymphomas, J Virol, 84, 3898, 10.1128/JVI.01321-09 Guasparri, 2006, The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling, EMBO Rep, 7, 114, 10.1038/sj.embor.7400580 Tomeczkowski, 1995, Absence of G-CSF receptors and absent response to G-CSF in childhood Burkitt's lymphoma and B-ALL cells, Br J Haematol, 89, 771, 10.1111/j.1365-2141.1995.tb08414.x Roy, 2011, Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines, Blood, 118, e32, 10.1182/blood-2010-12-323659 Toujani, 2009, High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma, PLoS One, 4, e7089, 10.1371/journal.pone.0007089 Uchida, 1999, Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses, Science, 286, 300, 10.1126/science.286.5438.300 Rastelli, 2008, LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1, Blood, 111, 1448, 10.1182/blood-2007-10-117655 Bellows, 2002, Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins, J Virol, 76, 2469, 10.1128/jvi.76.5.2469-2479.2002 Marshall, 1999, Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak, J Virol, 73, 5181, 10.1128/JVI.73.6.5181-5185.1999 Gregory, 2009, Toll-like receptor signaling controls reactivation of KSHV from latency, Proc Natl Acad Sci U S A, 106, 11725, 10.1073/pnas.0905316106 Fathallah, 2010, EBV latent membrane protein 1 is a negative regulator of TLR9, J Immunol, 185, 6439, 10.4049/jimmunol.0903459 Ohsaki, 2004, Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency, J Virol, 78, 9936, 10.1128/JVI.78.18.9936-9946.2004 Ko, 2012, Suppressive regulation of KSHV RTA with O-GlcNAcylation, J Biomed Sci, 19, 12, 10.1186/1423-0127-19-12 Lu, 2012, Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA, J Virol, 86, 5752, 10.1128/JVI.07216-11 Cusimano, 2009, Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth, Ann NY Acad Sci, 1155, 300, 10.1111/j.1749-6632.2009.03701.x Tober, 2006, Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development, J Invest Dermatol, 126, 205, 10.1038/sj.jid.5700014 Gupta, 2002, Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus, J Natl Cancer Inst, 94, 406, 10.1093/jnci/94.6.406 Xin, 2012, Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model, Laboratory Investigation, 92, 1115, 10.1038/labinvest.2012.90 Singh, 2011, Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human nonsmall cell lung cancer cells in vitro and in vivo, PLoS One, 6, e27444, 10.1371/journal.pone.0027444